Navigation Links
Novavax CEO to Present at BIO Investor Forum 2008
Date:10/28/2008

ROCKVILLE, Md., Oct. 28 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the BIO Investor Forum 2008 at 8:30 am. (PT) on October 30, 2008 at the Palace Hotel in San Francisco, California. Dr. Singhvi will provide an overview of the company's strategy, research and development progress. A link to the live presentation can be accessed via the Company website at http://www.novavax.com. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

ABOUT NOVAVAX

Novavax, Inc. (Nasdaq: NVAX) is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
2. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
3. Novavax Announces Closing of $18 Million Registered Direct Offering
4. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
5. Novavax to Join Russell 3000 Index
6. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
7. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax Reports First Quarter 2008 Financial Results
10. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
11. Novavax Opens Its First U.S. Vaccine Plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... 2016 , ... Franz Inc. , an early innovator ... been recognized As “ Best in Semantic Web Technology - USA & Leader ... it’s our priority to showcase prominent professionals who are excelling in their industry ...
(Date:2/3/2016)... 2016  With the growing need for better ... underway, therapies such as monoclonal antibodies, recombinant protein ... of indications are in high demand. Conventionally expression ... and production of these therapeutics. However, due to ... costs, novel approaches and novel expression systems are ...
(Date:2/3/2016)... ... February 03, 2016 , ... ProMIS Neurosciences ... targets (epitopes) specific to misfolded, propagating strains of Amyloid beta involved in Alzheimer’s ... therapeutics for Alzheimer’s. , Following on from the first misfolded Amyloid beta target ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... aid in the rapid development and ongoing quality control of molecular assays targeting ... is extremely high,” Dr. Gregory R. Chiklis, President and CEO of ZeptoMetrix, relayed ...
Breaking Biology Technology:
(Date:2/2/2016)... --Technology Enhancements Accelerate Growth of X-ray Imaging This ... computed radiography markets in Thailand , ... (TIM). It provides an in-depth analysis of ... regional market drivers and restraints. The study offers revenue ... attractiveness, both for digital and computed radiography. Market participants ...
(Date:2/1/2016)... BURNABY, Canada , February 1, 2016 ... new technological advancements to drive global touchfree intuitive gesture ...   --> Rising sales of consumer electronics ... intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ...
(Date:1/28/2016)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human ... December 31, 2015. --> --> ... 2 percent compared to the comparable quarter last year to $470.5 ... $35.0 million, or $0.93 per diluted share. ... quarter of fiscal 2016 grew 9 percent over the prior year ...
Breaking Biology News(10 mins):